Cargando…

A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sousa, Flávia, Cruz, Andrea, Fonte, Pedro, Pinto, Inês Mendes, Neves-Petersen, Maria Teresa, Sarmento, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473878/ https://www.ncbi.nlm.nih.gov/pubmed/28623267 http://dx.doi.org/10.1038/s41598-017-03959-4

Ejemplares similares

Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying
por: Fonte, Pedro, et al.
Publicado: (2012)

Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application
por: Moura, Catarina Costa, et al.
Publicado: (2014)

Evaluation of the Antitumour and Antiproliferative Effect of Xanthohumol-Loaded PLGA Nanoparticles on Melanoma
por: Fonseca, Magda, et al.
Publicado: (2021)

Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles
por: Fodor-Kardos, Andrea, et al.
Publicado: (2020)

Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data
por: Argyri, Katerina D., et al.
Publicado: (2016)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
por: Liu, Jiaxin, et al.
Publicado: (2019)

Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles †
por: Nozal, Vanesa, et al.
Publicado: (2021)

Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery
por: Lu, Boting, et al.
Publicado: (2019)

Enhanced Anticancer Activity of Hymenocardia acida Stem Bark Extract Loaded into PLGA Nanoparticles
por: Adedokun, Oluwasegun, et al.
Publicado: (2022)

Externally Controlled Triggered-Release of Drug from PLGA Micro and Nanoparticles
por: Hua, Xin, et al.
Publicado: (2014)

Counteracting the effect of leukemia exosomes by antiangiogenic gold nanoparticles
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2019)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

Preparation of PLGA Nanoparticles by Milling Spongelike PLGA Microspheres
por: Lee, Jimin, et al.
Publicado: (2022)

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
por: Choi, Yongwhan, et al.
Publicado: (2020)

Evaluation of Cell Proliferation and Wound Healing Effects of Vitamin A Palmitate-Loaded PLGA/Chitosan-Coated PLGA Nanoparticles: Preparation, Characterization, Release, and Release Kinetics
por: Baghirova, Lala, et al.
Publicado: (2023)

PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release
por: Halayqa, Mohammed, et al.
Publicado: (2014)

Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles
por: Kashyap, Sapna, et al.
Publicado: (2019)

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
por: Xu, Hui, et al.
Publicado: (2015)

Antiangiogenic properties of nanoparticles: a systematic review
por: Saeed, Brhaish Ali, et al.
Publicado: (2019)

A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles
por: Pourtalebi Jahromi, Leila, et al.
Publicado: (2020)

Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
por: Rusnati, Marco, et al.
Publicado: (2010)

Injectable In-Situ Forming Depot Based on PLGA and PLGA-PEG-PLGA for Sustained-Release of Risperidone: In Vitro Evaluation and Pharmacokinetics in Rabbits
por: Rezaeian Shiadeh, Seyedeh Nesa, et al.
Publicado: (2023)

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
por: Nishino, Mizuki, et al.
Publicado: (2012)

Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles
por: Pakulska, Malgosia M., et al.
Publicado: (2016)

Electrohydrodynamic fabrication of core–shell PLGA nanoparticles with controlled release of cisplatin for enhanced cancer treatment
por: Reardon, Philip JT, et al.
Publicado: (2017)

Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release
por: Dong, Ni, et al.
Publicado: (2020)

Biodegradable Nanoparticles-Loaded PLGA Microcapsule for the Enhanced Encapsulation Efficiency and Controlled Release of Hydrophilic Drug
por: Ryu, Suji, et al.
Publicado: (2021)

Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles
por: Vallorz, Ernest L., et al.
Publicado: (2022)

Diclofenac Loaded Biodegradable Nanoparticles as Antitumoral and Antiangiogenic Therapy
por: Esteruelas, Gerard, et al.
Publicado: (2022)

Double-Walled Poly-(D,L-lactide-co-glycolide) (PLGA) and Poly(L-lactide) (PLLA) Nanoparticles for the Sustained Release of Doxorubicin
por: Cardoso, M. Margarida, et al.
Publicado: (2021)

PLGA-Based Nanoparticles in Cancer Treatment
por: Rezvantalab, Sima, et al.
Publicado: (2018)

PEG–PLGA nanoparticles for encapsulating ciprofloxacin
por: Watcharadulyarat, Natsorn, et al.
Publicado: (2023)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
por: Rafiei, Pedram, et al.
Publicado: (2017)

Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
por: Babos, György, et al.
Publicado: (2018)

Reduced Cardiotoxicity of Ponatinib-Loaded PLGA-PEG-PLGA Nanoparticles in Zebrafish Xenograft Model
por: Al-Thani, Hissa F., et al.
Publicado: (2022)

Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
por: Anwer, Md Khalid, et al.
Publicado: (2019)

Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy
por: Lee, Pei-Chi, et al.
Publicado: (2019)

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
por: Kim, Jeongrae, et al.
Publicado: (2022)

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats
por: Wang, Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6q78cdk8js5ht5cseldmdqvctk